BRPI0506705A - composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos - Google Patents
composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usosInfo
- Publication number
- BRPI0506705A BRPI0506705A BRPI0506705-7A BRPI0506705A BRPI0506705A BR PI0506705 A BRPI0506705 A BR PI0506705A BR PI0506705 A BRPI0506705 A BR PI0506705A BR PI0506705 A BRPI0506705 A BR PI0506705A
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- compounds
- pharmaceutical compositions
- compound
- suffering
- Prior art date
Links
- 239000008194 pharmaceutical composition Chemical class 0.000 title abstract 3
- 150000003585 thioureas Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 9
- 208000035473 Communicable disease Diseases 0.000 abstract 4
- 241001465754 Metazoa Species 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000029812 viral genome replication Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53483904P | 2004-01-06 | 2004-01-06 | |
| PCT/US2005/000339 WO2005067900A2 (en) | 2004-01-06 | 2005-01-05 | Azabenzofuran substituted thioureas as inhibitors of viral replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0506705A true BRPI0506705A (pt) | 2007-05-02 |
Family
ID=34794326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0506705-7A BRPI0506705A (pt) | 2004-01-06 | 2005-01-05 | composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7439374B2 (https=) |
| EP (1) | EP1709047B1 (https=) |
| JP (1) | JP2007517887A (https=) |
| KR (1) | KR20060121289A (https=) |
| CN (1) | CN1946720A (https=) |
| AP (1) | AP2006003659A0 (https=) |
| AR (1) | AR047367A1 (https=) |
| AT (1) | ATE479684T1 (https=) |
| AU (1) | AU2005204369B2 (https=) |
| BR (1) | BRPI0506705A (https=) |
| CA (1) | CA2552002A1 (https=) |
| DE (1) | DE602005023266D1 (https=) |
| EA (1) | EA200601281A1 (https=) |
| IL (1) | IL176486A0 (https=) |
| NO (1) | NO20062928L (https=) |
| NZ (1) | NZ548375A (https=) |
| OA (1) | OA13357A (https=) |
| TW (1) | TW200528459A (https=) |
| WO (1) | WO2005067900A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200600492A (en) * | 2004-05-18 | 2006-01-01 | Achillion Pharmaceuticals Inc | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication |
| TWI329102B (en) * | 2006-08-15 | 2010-08-21 | Nat Health Research Institutes | Thiourea compounds and method for inhibiting hepatitis c virus infection |
| BRPI0715714A2 (pt) * | 2006-08-25 | 2014-03-11 | Wyeth Corp | Métodos para diminuir a frequência de emergência de uma infecção viral de hepatite c resistente ao tratamento, para atrasar a emergência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir o nível de resistência de uma infecção viral de hepatite c resistente ao tratamento, para diminuir a emergência de uma infecção viral de hepatite c resistente a hcv-796, para identificar um indivíduo com uma probabilidade diminuída de responder a uma terapia viral anti-hepatite c, para monitorar, diagnosticar ou prognosticar a infecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar o curso de tratamento de uma infecção viral de hepatite c em um paciente, para prognosticar o desenvolvimento de um ainfecção viral de hepatite c resistente ao tratamento em um paciente, para monitorar a infecção viral de hepatite c em um paciente e para diagnosticar o desenvolvimento de uma infecção viral de hepatite ao tratamento em um paciente |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2008124300A1 (en) * | 2007-04-10 | 2008-10-16 | National Health Research Institutes | Hepatitis c virus inhibitors |
| TW200848016A (en) * | 2007-06-08 | 2008-12-16 | Nat Health Research Institutes | Thiourea compound and composition of treating hepatitis C virus infection |
| TWI361808B (en) * | 2008-01-08 | 2012-04-11 | Nat Health Research Institutes | Imidazolidinone and imidazolidinethione derivatives |
| US8198284B2 (en) * | 2008-04-30 | 2012-06-12 | National Health Research Institutes | Treatment of neurodegenerative disorders with thiourea compounds |
| US8198449B2 (en) * | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| SG194404A1 (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| KR20110098849A (ko) | 2008-12-23 | 2011-09-01 | 파마셋 인코포레이티드 | 뉴클레오시드 유사체 |
| PT2376088T (pt) | 2008-12-23 | 2017-05-02 | Gilead Pharmasset Llc | Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| UY33312A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidato de nucleosido de purina |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| PT2609923T (pt) | 2010-03-31 | 2017-08-30 | Gilead Pharmasset Llc | Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo |
| AR082453A1 (es) | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
| AU2011336632B2 (en) | 2010-11-30 | 2015-09-03 | Gilead Pharmasset Llc | Compounds |
| PL2709613T5 (pl) | 2011-09-16 | 2020-12-14 | Gilead Pharmasset Llc | Metody leczenia hcv |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| CN103467482B (zh) * | 2012-04-10 | 2017-05-10 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用 |
| PT2950786T (pt) | 2013-01-31 | 2020-03-03 | Gilead Pharmasset Llc | Formulação de combinação de dois compostos antivirais |
| EA201690473A1 (ru) | 2013-08-27 | 2017-03-31 | ГАЙЛИД ФАРМАССЕТ ЭлЭлСи | Комбинированный состав двух противовирусных соединений |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR20240026521A (ko) | 2017-03-23 | 2024-02-28 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| EP4717317A2 (en) | 2017-06-20 | 2026-04-01 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1408198A (en) * | 1971-08-23 | 1975-10-01 | Medizinska Akad | Antiviral compositions |
| CN1071930A (zh) * | 1991-07-10 | 1993-05-12 | 伊莱利利公司 | 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂 |
| GB9504460D0 (en) | 1995-03-06 | 1995-04-26 | Bayer Ag | N-(3-Benzofuranyl)urea-derivatives |
| CA2253502A1 (en) * | 1996-05-06 | 1997-11-13 | Stephen Warren Kaldor | Anti-viral compounds |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| CN1731993A (zh) | 2002-11-01 | 2006-02-08 | 维洛药品公司 | 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法 |
| CN1738797A (zh) * | 2002-11-19 | 2006-02-22 | 阿基里昂药品公司 | 取代的芳基硫脲和相关的化合物,病毒复制的抑制剂 |
| CA2531068A1 (en) * | 2003-07-10 | 2005-01-27 | Achillion Pharmaceuticals, Inc. | Substituted arylthiourea derivatives useful as inhibitors of viral replication |
-
2004
- 2004-12-30 TW TW093141409A patent/TW200528459A/zh unknown
-
2005
- 2005-01-05 DE DE602005023266T patent/DE602005023266D1/de not_active Expired - Lifetime
- 2005-01-05 EA EA200601281A patent/EA200601281A1/ru unknown
- 2005-01-05 CA CA002552002A patent/CA2552002A1/en not_active Abandoned
- 2005-01-05 KR KR1020067013660A patent/KR20060121289A/ko not_active Withdrawn
- 2005-01-05 AU AU2005204369A patent/AU2005204369B2/en not_active Ceased
- 2005-01-05 AR ARP050100026A patent/AR047367A1/es not_active Application Discontinuation
- 2005-01-05 WO PCT/US2005/000339 patent/WO2005067900A2/en not_active Ceased
- 2005-01-05 OA OA1200600222A patent/OA13357A/en unknown
- 2005-01-05 NZ NZ548375A patent/NZ548375A/en unknown
- 2005-01-05 BR BRPI0506705-7A patent/BRPI0506705A/pt not_active IP Right Cessation
- 2005-01-05 CN CNA200580007223XA patent/CN1946720A/zh active Pending
- 2005-01-05 JP JP2006549390A patent/JP2007517887A/ja active Pending
- 2005-01-05 AP AP2006003659A patent/AP2006003659A0/xx unknown
- 2005-01-05 US US11/029,910 patent/US7439374B2/en not_active Expired - Fee Related
- 2005-01-05 AT AT05705124T patent/ATE479684T1/de not_active IP Right Cessation
- 2005-01-05 EP EP05705124A patent/EP1709047B1/en not_active Expired - Lifetime
-
2006
- 2006-06-21 IL IL176486A patent/IL176486A0/en unknown
- 2006-06-22 NO NO20062928A patent/NO20062928L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005067900A2 (en) | 2005-07-28 |
| AU2005204369A1 (en) | 2005-07-28 |
| EP1709047B1 (en) | 2010-09-01 |
| NZ548375A (en) | 2010-07-30 |
| EA200601281A1 (ru) | 2006-12-29 |
| CA2552002A1 (en) | 2005-07-28 |
| TW200528459A (en) | 2005-09-01 |
| EP1709047A2 (en) | 2006-10-11 |
| AP2006003659A0 (en) | 2006-06-30 |
| WO2005067900A3 (en) | 2005-09-29 |
| AU2005204369B2 (en) | 2010-06-10 |
| JP2007517887A (ja) | 2007-07-05 |
| US7439374B2 (en) | 2008-10-21 |
| OA13357A (en) | 2007-04-13 |
| AR047367A1 (es) | 2006-01-18 |
| DE602005023266D1 (de) | 2010-10-14 |
| US20050228013A1 (en) | 2005-10-13 |
| ATE479684T1 (de) | 2010-09-15 |
| KR20060121289A (ko) | 2006-11-28 |
| NO20062928L (no) | 2006-08-03 |
| IL176486A0 (en) | 2006-10-05 |
| CN1946720A (zh) | 2007-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0506705A (pt) | composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos | |
| BR0316397A (pt) | Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral | |
| UA92746C2 (en) | Thiazole compounds and methods of use | |
| TW200600492A (en) | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | |
| Mirtaleb et al. | Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy | |
| Geier et al. | A review of Thimerosal (Merthiolate) and its ethylmercury breakdown product: specific historical considerations regarding safety and effectiveness | |
| Imran et al. | Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review | |
| ES2988617T3 (es) | Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales | |
| BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
| ES2187575T3 (es) | Hexapeptidos ciclicos dotados de actividad antibiotica. | |
| BR0309670A (pt) | Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo | |
| KR20120044930A (ko) | 고병원성 감염성 질환의 예방 및 치료제 | |
| BR112022019198A2 (pt) | Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma | |
| WO2005095345A3 (en) | Heteroaryl guanidines as inhibitors of viral replication | |
| BRPI0407140A (pt) | Droga terapêutica para vìrus | |
| RU2738719C1 (ru) | Средство для лечения коронавирусных, ретровирусных инфекций и гепатита с | |
| EA202100186A3 (ru) | Вакцина и способ защиты от коронавирусной инфекции | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| WO2021195185A1 (en) | Method of treating coronavirus infection by administration of ethyl mercury or thiol derivative thereof | |
| KR20060054190A (ko) | 코로나 바이러스를 불활성화시키는 제제 | |
| RU2420309C2 (ru) | Препарат против бешенства | |
| RU2259843C1 (ru) | Способ лечения миксоматоза кроликов | |
| RU2188001C2 (ru) | Способ лечения миксоматоза и вирусной геморрагической болезни кроликов | |
| RU2009112724A (ru) | Циклические сульфоны в качестве митохондриальных натрий-кальциевых обменников | |
| Waghchaure et al. | A REVIEW ON: COVID-19, THE STEP TOWARDS PREVENTION, TREATMENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |